Hubbry Logo
MicrococcusMicrococcusMain
Open search
Micrococcus
Community hub
Micrococcus
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Micrococcus
Micrococcus
Micrococcus
View on Wikipedia
from Wikipedia

Micrococcus
Micrococcus mucilaginosis
Scientific classification Edit this classification
Domain: Bacteria
Kingdom: Bacillati
Phylum: Actinomycetota
Class: Actinomycetes
Order: Micrococcales
Family: Micrococcaceae
Genus: Micrococcus
Cohn 1872
Type species
Micrococcus luteus
(Schroeter 1872) Cohn 1872 (Approved Lists 1980)
Species

Micrococcus, from Ancient Greek μικρός (mikrós), meaning "small", and κόκκος (kókkos), meaning "sphere", is a genus of bacteria in the Micrococcaceae family. Micrococcus occurs in a wide range of environments, including water, dust, and soil. Micrococci have Gram-positive spherical cells ranging from about 0.5 to 3 micrometers in diameter and typically appear in tetrads. They are catalase positive, oxidase positive, indole negative and citrate negative. Micrococcus has a substantial cell wall, which may comprise as much as 50% of the cell mass. The genome of Micrococcus is rich in guanine and cytosine (GC), typically exhibiting 65 to 75% GC-content. Micrococci often carry plasmids (ranging from 1 to 100 MDa in size) that provide the organism with useful traits.

Some species of Micrococcus, such as M. luteus (yellow) and M. roseus (red) produce yellow or pink colonies when grown on mannitol salt agar. Isolates of M. luteus have been found to overproduce riboflavin when grown on toxic organic pollutants like pyridine.[1]

Taxonomy

[edit]

Hybridization studies from 1995 indicate that species within the genus Micrococcus are not closely related, showing as little as 50% sequence similarity.[2] This suggests that some Micrococcus species may, on the basis of ribosomal RNA analysis, eventually be re-classified into other microbial genera.

The following species have been reclassified since then:

The following names were not included in the Approved Lists of 1980:

  • "M. candicans"
  • "M. cryophilus"
  • "M. diversus"
  • "M. prodigiosus"
  • "M. radiodurans"
  • "M. radioproteolyticus"
  • "M. sodonensis"

In addition, GTDB (revision 214) indicates that Micrococcus terreus likely belongs in Citricoccus.[3]

Environmental

[edit]

Micrococci have been isolated from human skin, animal and dairy products, and beer. They are found in many other places in the environment, including water, dust, and soil. M. luteus on human skin transforms compounds in sweat into compounds with an unpleasant odor. Micrococci can grow well in environments with little water or high salt concentrations, including sportswear made with synthetic fabrics.[4] Most are mesophiles; some, like Micrococcus antarcticus (found in Antarctica) are psychrophiles.

Though not a spore former, Micrococcus cells can survive for an extended period of time, both at refrigeration temperatures, and in nutrient-poor conditions such as sealed in amber.[5][6]

Pathogenesis

[edit]

Micrococcus is generally thought to be a saprotrophic or commensal organism, though it can be an opportunistic pathogen, particularly in hosts with compromised immune systems, such as HIV patients.[7] It can be difficult to identify Micrococcus as the cause of an infection, since the organism is normally present in skin microflora, and the genus is seldom linked to disease. In rare cases, death of immunocompromised patients has occurred from pulmonary infections caused by Micrococcus. Micrococci may be involved in other infections, including recurrent bacteremia, septic shock, septic arthritis, endocarditis, meningitis, and cavitating pneumonia (immunosuppressed patients).

Industrial uses

[edit]

Micrococci, like many other representatives of the Actinobacteria, can be catabolically versatile, with the ability to utilize a wide range of unusual substrates, such as pyridine, herbicides, chlorinated biphenyls, and oil.[8][9] They are likely involved in detoxification or biodegradation of many other environmental pollutants.[10] Other Micrococcus isolates produce various useful products, such as long-chain (C21-C34) aliphatic hydrocarbons for lubricating oils.

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Micrococcus

View on Grokipedia
from Grokipedia
Micrococcus is a of Gram-positive, aerobic belonging to the family , characterized by spherical, nonmotile, non-spore-forming cocci that typically occur in tetrads or irregular clusters and measure 0.5–2.0 μm in diameter. These are - and oxidase-positive, chemo-organotrophic with strictly respiratory metabolism, and possess high DNA G+C content ranging from 69–76 mol%. Many species produce vividly pigmented colonies, often yellow due to , and thrive mesophilically at temperatures between 25–37°C without requiring high salt concentrations. Taxonomically, Micrococcus was first described by in 1872, with the Micrococcus luteus, and has undergone emendations to refine its boundaries, currently encompassing nine valid such as M. antarcticus, M. endophyticus, M. flavus, and M. yunnanensis. The genus falls within the , class Actinomycetia, order , and family , distinguished by types A2 or A4α containing L-lysine, major menaquinones like MK-8 or MK-7(H₂), and predominant fatty acids such as C_{15:0} anteiso and C_{15:0} iso. Genomic analyses reveal small chromosomes under 3 Mb, with limited biosynthetic gene clusters for secondary metabolites compared to other actinomycetes. Micrococcus species are ubiquitous environmental bacteria found in diverse habitats, including soil, freshwater, marine sediments, air, dairy products, and as commensals on human skin and animal tissues. They play ecological roles in nutrient cycling, such as oil degradation and plant growth promotion, and are generally non-pathogenic but can act as opportunistic pathogens in immunocompromised individuals, causing rare infections like bacteremia or endocarditis. In biotechnology, Micrococcus strains are valued for producing bioactive compounds with antibacterial, antifungal, antioxidant, and anti-inflammatory properties, including characterized metabolites like micrococcin and kocurin, positioning them as promising sources for novel drug discovery, particularly from marine isolates.

Taxonomy and characteristics

Etymology and history

The genus name Micrococcus originates from the terms mikrós (μικρός), meaning "small," and kókkos (κόκκος), meaning "" or "," alluding to the diminutive spherical morphology of the bacteria. This nomenclature reflects the early microscopic observations of these Gram-positive cocci, which appeared as tiny, berry-like clusters under primitive light microscopes. The Micrococcus was formally established in 1872 by the German botanist and microbiologist , who described the Micrococcus luteus (originally noted by J. C. G. de la Mortola as Bacterium luteum in 1853 but reclassified by Cohn) based on its yellow pigmentation and occurrence in environmental samples. Cohn's work built on the foundational of the era, classifying these organisms as non-motile, spherical distinct from rods or chains, marking an initial step in amid debates over . Earlier in the , had observed similar small spherical microbes, later termed micrococci, ubiquitous in air and during his experiments on and airborne contamination, though he did not formally name the . Key milestones in understanding Micrococcus evolved from these 19th-century morphological descriptions to 20th-century biochemical and physiological analyses. For instance, in 1922, isolated a strain of M. luteus (initially named Micrococcus lysodeikticus) from nasal to study the enzyme , highlighting its role in bacterial and advancing insights into its non-pathogenic, saprophytic nature. Subsequent studies in the mid-20th century, including pigment analysis and metabolic profiling, refined the genus's boundaries, distinguishing it from related actinobacteria through nutritional requirements and composition.

Classification and species

The genus Micrococcus is classified within the Actinomycetota, class Actinomycetia, order Micrococcales, and family . This taxonomic position reflects its placement among high G+C-content , supported by phylogenetic analyses of 16S rRNA gene sequences that delineate the genus from closely related taxa. Phylogenetic studies utilizing 16S rRNA sequencing have been instrumental in refining the boundaries, with an emended in 2002 distinguishing Micrococcus from genera like Arthrobacter through a polyphasic approach incorporating chemotaxonomic markers (e.g., cell-wall type A4α, major menaquinone MK-8(H4)) and phenotypic traits. This revision emphasized the genus's coherence as a monophyletic group within the , excluding species reassigned to genera such as and Dermacoccus based on genetic divergences exceeding 3% in 16S rRNA similarity thresholds. As of 2025, 10 species are recognized in the Micrococcus. Key species include the Micrococcus luteus, notable for its yellow pigmentation due to production and frequent isolation from and mammalian ; M. lylae, which exhibits white to creamy colonies and is primarily associated with human ; M. flavus, distinguished by bright yellow pigmentation and common in dust, air, and settings; M. antarcticus, isolated from ; M. endophyticus, a ; M. yunnanensis, from roots; M. aloeverae, from leaves; and M. lacusdianchii, a recent isolate from 2024.

Morphology and physiology

Micrococcus species are Gram-positive cocci characterized by their spherical shape, with cell diameters typically ranging from 0.5 to 2.0 μm. These bacteria are non-motile and non-spore-forming, often appearing in pairs, tetrads, or irregular clusters under microscopic examination. Some species exhibit pigmentation, such as the yellow colonies produced by Micrococcus luteus, which result from the accumulation of carotenoid pigments like sarcinaxanthin and zeaxanthin that provide antioxidant protection. The cell wall of Micrococcus is composed of a thick peptidoglycan layer containing L-lysine as the diamino acid, forming an A2 or A4α linkage type that contributes to its Gram-positive staining. Unlike many other Gram-positive bacteria, Micrococcus lacks teichoic acids, though teichuronic acids may be present in some species, and mannosamine-uronic acid can occur in cell wall polysaccharides. Physiologically, Micrococcus is strictly aerobic and chemo-organotrophic, relying on respiratory metabolism for energy derivation. It is catalase-positive and oxidase-positive, facilitating the breakdown of and electron transfer in respiration, respectively. Optimal growth occurs at mesophilic temperatures between 25 and 37°C and neutral to slightly alkaline pH values of 7 to 8, with growth reduced below pH 6 or above 45°C. These do not form spores and grow well on simple media, demonstrating up to 5% NaCl. Metabolically, Micrococcus utilizes sugars and through oxidative respiration, producing minimal acid from carbohydrates and exhibiting proteolytic, lipolytic, and activities via enzymes such as metalloproteinases, proteinases, and . The respiratory chain includes (e.g., aa3, b557) and dehydrogenases that support the oxidation of substrates, enabling efficient energy production under aerobic conditions.

Ecology and distribution

Natural habitats

_Micrococcus species are ubiquitous bacteria found in a wide array of non-host natural environments, including soil, freshwater, marine waters, dust, and air. These Gram-positive cocci play a key role in nutrient cycling through the decomposition of organic matter, contributing to the breakdown of complex substrates and facilitating the release of essential nutrients like nitrogen via processes such as nitrate reduction. The genus exhibits notable environmental adaptations that enable survival in challenging conditions. Pigmentation, particularly carotenoids produced by species like Micrococcus luteus, provides protection against ultraviolet (UV) radiation and desiccation by absorbing harmful wavelengths and mitigating oxidative stress. Additionally, Micrococcus thrives in oligotrophic environments with low nutrient availability, switching metabolic processes to endure nutrient scarcity and low water activity. Micrococcus displays a global distribution, occurring worldwide from temperate soils to extreme locales. Representatives have been isolated from and soils, tropical freshwater systems, and marine habitats ranging from surface waters to deep-sea sediments at depths exceeding 4,000 meters, such as in the . This broad presence underscores their resilience across diverse climatic and geochemical gradients. In microbial communities, Micrococcus acts as a commensal, integrating into and aquatic microbiomes to enhance overall diversity. Their metabolic contributions, including degradation, support stability by promoting turnover and fostering interactions with other decomposers in these environments.

Human and animal associations

Micrococcus species are commonly found as part of the normal microbial on , where they colonize various body sites including the face, arms, and legs, often comprising a small but consistent proportion of the cutaneous . These also inhabit mucous membranes, such as those in the nasal passages and upper , contributing to the resident commensal community without typically causing harm. In the oral cavity, Micrococcus has been detected on and gingival surfaces, where it persists as a non-dominant but regular component of the diverse oral . In animals, Micrococcus species similarly associate with skin surfaces, particularly the teat skin of , where they form part of the natural epifauinal and can transfer to during . They have also been isolated from the gut environments of , such as the of pigs, indicating a role in intestinal microbial communities under certain conditions. In veterinary contexts, Micrococcus is frequently recovered from skin swabs and dairy products like , highlighting its relevance in hygiene monitoring. Colonization by Micrococcus in host environments is facilitated by adhesion mechanisms involving surface proteins that enable attachment to epithelial cells and components on nutrient-limited surfaces like . These thrive in low-competition niches due to their aerobic and tolerance to the relatively dry, saline conditions of host exteriors, allowing persistent but benign residency. In clinical and veterinary , Micrococcus is routinely identified as a common contaminant in samples from human and animal sources, often dismissed after initial isolation unless multiple colonies suggest otherwise. Detection typically involves Gram staining to reveal the characteristic tetrad-forming cocci, followed by biochemical tests like positivity and activity, or advanced methods such as matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF MS) for rapid species-level confirmation.

Pathogenicity and clinical significance

Opportunistic infections

Micrococcus species are primarily opportunistic pathogens that rarely cause infections in healthy individuals but can lead to serious conditions in immunocompromised hosts, such as those undergoing or with indwelling medical devices. Common infection types include bacteremia, , , and , often associated with underlying malignancies, invasive procedures, or prosthetic materials. For instance, bacteremia typically presents with fever and elevated inflammatory markers in patients with risk factors like central venous catheters. cases are infrequent and predominantly involve prosthetic valves, though native valve involvement has been documented in patients with post-. manifests as acute joint pain and swelling, usually in patients with prior joint surgeries or . , though rare, has been reported as community-acquired in otherwise healthy adults, featuring , fever, and infiltrates confirmed by imaging, including cases caused by M. antarcticus as of 2024. Epidemiologically, Micrococcus infections exhibit low incidence, with bloodstream infections (BSI) occurring at approximately 6.7 per 100,000 admissions in tertiary care settings (based on 2010–2019 data from a Chinese hospital), representing about 0.95% of all BSIs. The most frequently implicated species is M. luteus, accounting for the majority of cases since the 1980s, when initial reports emerged; detection has increased due to advanced molecular methods like MALDI-TOF mass spectrometry and 16S rRNA sequencing. Risk factors include malignancy (present in nearly 50% of BSI cases), recent invasive surgery (around 40%), and indwelling catheters (about 38%), with over two-thirds of patients having at least one such factor. Infections are predominantly hospital-acquired (over 70%), affecting a broad age range but skewing toward adults over 50 years, with no strong gender predominance. Case reports highlight sporadic occurrences, such as cholangitis in diabetic patients (including a 2024 case due to M. lylae), meningitis in those with shunts (and other meningitis cases), or urinary tract infections associated with catheters (e.g., M. lylae in 2023), underscoring the role of breaches in host barriers and emerging involvement of species beyond M. luteus. Intracranial infections, such as abscesses mimicking brain tumors caused by M. luteus, have also been reported as of 2025. Diagnosis relies on clinical suspicion in at-risk patients, supported by microbiological confirmation. Gram staining reveals characteristic Gram-positive cocci arranged in tetrads or clusters from clinical specimens like blood, synovial fluid, or . Cultures on blood agar yield small, yellow-pigmented colonies after 24-48 hours of aerobic incubation. Species identification is achieved via automated systems like VITEK 2 or molecular techniques, with BSI defined by at least two consecutive positive blood cultures alongside symptoms such as fever or . Antibiotic susceptibility testing shows general responsiveness, though patterns vary; most strains are susceptible to , cephalosporins, and quinolones, but resistance to erythromycin and occasional isolates to gentamicin or has been noted. Treatment involves prompt tailored to susceptibility results, often starting empirically with broad-spectrum agents like cephalosporins (used in about 60% of BSI cases) or for severe presentations. Definitive regimens commonly include cephalosporins or glycopeptides for 4-6 weeks, with adjunctive measures like device removal in or drainage in . demonstrates strong activity, with large zones of inhibition. Outcomes are favorable, with survival rates exceeding 95% in reported series; mortality is low (around 3%) and typically attributable to comorbidities rather than the infection itself, as seen in cases resolved with 1-2 weeks of for or extended courses for .

Virulence mechanisms

Micrococcus , including the commonly studied M. luteus, are generally regarded as low-virulence commensals but can contribute to opportunistic infections through mechanisms that promote , , and mild tissue disruption. These lack the robust arsenal of more aggressive pathogens, relying instead on adaptive strategies for survival in host environments, particularly in immunocompromised individuals or on indwelling devices. A primary virulence mechanism is biofilm formation, which enables Micrococcus to colonize abiotic surfaces such as medical devices and human skin, shielding cells from antibiotics and immune clearance. In M. luteus, biofilms exhibit structural integrity provided by extracellular DNA (eDNA), which forms a mesh with polysaccharides and proteins to enhance adhesion and aggregation; treatment with DNase I disrupts this structure, reducing adhesion forces by over 90%. Environmental factors like epinephrine further modulate biofilm matrix composition by elevating levels of polysaccharides, eDNA, and proteins such as EF-Tu, thereby increasing stability and persistence during stress conditions like starvation. Genomic analyses confirm the presence of accessory genes supporting biofilm-related processes, including sortase enzymes that anchor surface proteins to the cell wall. Extracellular enzymes facilitate limited tissue by degrading host components. M. luteus strains produce proteases, such as those encoded by the pafA , which contribute to acquisition and subtle host tissue breakdown. Lipolytic activity is supported by β-oxidation enzymes encoded by fadA, fadB, and fadE , enabling the of host . These enzymes, while not as aggressive as those in species, aid opportunistic spread in vulnerable sites. Immune evasion relies on resistance to phagocytosis and oxidative stress. Certain M. luteus isolates harbor genes like wbjD/wecB, wecC, and gnd, which promote antiphagocytic properties potentially through capsule-like polysaccharide structures. Antioxidant defenses include superoxide dismutase (sodA) and catalase (katA), which neutralize reactive oxygen species from the host's oxidative burst, enhancing survival within phagocytes. Adhesion to host tissues is mediated by genes such as htpB, bauE, and sortase (OG_2452), with Flp pili further supporting colonization; these factors have been identified in genomic surveys of clinical isolates. The genetic underpinnings of virulence include core and accessory genes for antibiotic resistance, such as mtrA, murA, rbpA, and strA, which confer tolerance to agents like streptomycin and macrolides, though plasmid-mediated resistance is rare. Toxin production remains minimal, with genomic databases revealing few hits for potent hemolysins or cytotoxins compared to high-impact pathogens. Studies on M. luteus clinical isolates, including those from bloodstream infections, highlight the role of these adhesion and stress-response genes in low-level pathogenicity, as demonstrated in insect models showing dose-dependent but limited mortality. Overall, virulence factor databases report hundreds of potential hits per strain (e.g., 527 in one isolate), underscoring nascent adaptations for opportunistic niches without high lethality.

Applications and research

Industrial and biotechnological uses

Micrococcus species, particularly M. luteus, play a role in the through their involvement in processes. In surface-ripened cheeses such as smear-ripened varieties, Micrococcus contributes to flavor development by producing proteolytic and lipolytic enzymes that break down proteins and fats, enhancing texture and aroma. These bacteria are naturally present or added as part of starter cultures alongside , aiding in the deacidification and maturation of cheeses like and . Additionally, pigments produced by Micrococcus strains, such as the yellow from M. luteus, offer potential as natural colorants in products, providing stable, non-toxic alternatives to synthetic dyes. In , Micrococcus species are utilized for degrading hydrocarbons and other pollutants in contaminated environments. Strains like M. luteus exhibit capabilities to break down hydrocarbons in through enzymatic activity, facilitating the cleanup of oil-spill sites. They are also employed in systems, where they contribute to the organic breakdown of pollutants, including and , improving effluent quality in processes. Other industrial applications include production, notably catalases from Micrococcus used in detergents to decompose residues from bleaching agents, enhancing cleaning efficiency. Historically, Micrococcus luteus has served as an in air quality testing due to its ubiquity in airborne environments, helping assess microbial levels in settings like pharmaceutical cleanrooms and facilities. Micrococcus species are considered safe for food applications due to their long history of use in without reported adverse effects, as indicated in regulatory assessments. Their low pathogenicity and robust metabolic profiles support safe incorporation in industrial processes.

Recent discoveries in bioactivity

Recent research has identified Micrococcus species as promising sources for novel bioactive compounds with antibacterial properties. For instance, crude pigment extracts from Micrococcus sp. MP76 demonstrated activity against , , and , with minimum inhibitory concentrations indicating potential as broad-spectrum agents. Similarly, extracts from Micrococcus sp. KRD strains exhibited antibacterial effects against S. aureus and E. coli, highlighting the genus's capacity to produce inhibitory metabolites suitable for . Antifungal bioactivities have also been documented, particularly from carotenoid compounds. The pigment echinenone isolated from Micrococcus lylae YH3 showed significant antifungal activity in bioassays, suggesting applications against fungal pathogens. Cytotoxic compounds from Micrococcus further expand its therapeutic potential; the MY3 pigment from Micrococcus terreus JGI 19 exhibited cytotoxicity against cervical and liver cancer cell lines, with IC50 values underscoring selective antiproliferative effects. Echinenone from M. lylae YH3 similarly displayed cytotoxic properties, supporting ongoing investigations into Micrococcus-derived anticancer agents. Antioxidant properties of Micrococcus species arise primarily from production, offering therapeutic promise for oxidative stress-related conditions. Crude pigments from Micrococcus sp. MP76 neutralized free radicals effectively in assays, while echinenone from M. lylae YH3 provided robust scavenging activity, potentially mitigating diseases like neurodegeneration. such as sarcinaxanthin and , commonly produced by the genus, contribute to cellular protection against , as evidenced by their role in reducing oxidative damage in model systems. Emerging applications include the potential of in . A clinical study on topical serum containing live M. luteus Q24 reported significant improvements, including 51% reduction in pores, 50% in spots, 46% in wrinkles, and 101% increase in hydration after 25 days of application in healthy adults, with no adverse effects and enhanced . A 2025 pilot study on M. luteus Q24 balms further confirmed these benefits, achieving up to 100% reduction in pores and , alongside boosted hydration, positioning the bacterium as a microbiome-friendly skincare ingredient. Genomic sequencing has revealed biosynthetic gene clusters (BGCs) in Micrococcus genomes that underpin these bioactivities. Analysis of 52 Micrococcus genomes identified multiple BGCs associated with production, including and polyketides, facilitating targeted discovery of novel compounds. Studies have demonstrated cytotoxic activity of Micrococcus extracts against various lines, aligning with predictions from BGC analyses. In 2025, crude extracts from a marine-derived M. luteus strain exhibited antitumor activity against colorectal () and hepatocellular (HepG-2) carcinoma cells, reducing cell viability to 12–37% at 8 µg/µL concentrations and inducing through increased Bax/ ratio (up to 14.25-fold) and expression (up to 7.79-fold). Challenges in scaling production from laboratory isolates to therapeutic levels persist due to low yield optimization.

References

  1. https://onlinelibrary.wiley.com/doi/10.1002/9781118960608.gbm00121
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC10548855/
  3. https://lpsn.dsmz.de/genus/micrococcus
  4. https://www.oed.com/dictionary/micrococcus_n
  5. https://academic.oup.com/femsre/article/24/3/225/561657
  6. https://www.gutenberg.org/files/47505/47505-h/47505-h.htm
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC2812450/
  8. https://pubmed.ncbi.nlm.nih.gov/11931177/
  9. https://www.ncbi.nlm.nih.gov/datasets/taxonomy/1269/
  10. https://doi.org/10.1099/00207713-45-4-682
  11. https://www.sciencedirect.com/topics/immunology-and-microbiology/micrococcus
  12. https://bmcbiotechnol.biomedcentral.com/articles/10.1186/s12896-024-00899-6
  13. https://www.sciencedirect.com/topics/medicine-and-dentistry/micrococcus
  14. https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/micrococcus.html
  15. https://microbewiki.kenyon.edu/index.php/Micrococcus
  16. https://www.canada.ca/en/environment-climate-change/services/evaluating-existing-substances/screening-assessment-micrococcus-luteus.html
  17. https://www.researchgate.net/publication/321159758_Antimicrobial_activity_of_Micrococcus_luteus_Cartenoid_pigment
  18. https://erem.ktu.lt/index.php/erem/article/view/23832/14756
  19. https://microbewiki.kenyon.edu/index.php/Micrococcus_luteus
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC8354530/
  21. https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-021-07432-5
  22. https://www.sciencedirect.com/science/article/pii/S0304389421009602
  23. https://www.ncbi.nlm.nih.gov/books/NBK7617/
  24. https://www.sciencedirect.com/topics/medicine-and-dentistry/micrococcaceae
  25. https://www.researchgate.net/publication/10622473_Occurrence_and_number_of_bacteria_from_genera_Micrococcus_Kocuria_Nesterenkonia_Kytococcus_and_Dermacoccus_on_human_skin_and_mucous_membranes
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC9697426/
  27. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/micrococcus
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6921130/
  29. https://onlinelibrary.wiley.com/doi/abs/10.1002/9781683670438.mcm0021
  30. https://wickhammicro.co.uk/knowledge-and-education/micrococcus-luteus
  31. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-024-10084-x
  32. https://pubmed.ncbi.nlm.nih.gov/39220420/
  33. https://pubmed.ncbi.nlm.nih.gov/37515797/
  34. https://journals.lww.com/nuclearmed/fulltext/2025/08000/intracranial_micrococcus_luteus_infection.25.aspx
  35. https://ijmmtd.org/archive/volume/5/issue/1/article/8565
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC8459002/
  37. https://pubmed.ncbi.nlm.nih.gov/3735296/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC9726359/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC7890812/
  40. https://eprints.whiterose.ac.uk/145192/
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC9530943/
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC10770869/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC4993860/
  44. https://journals.asm.org/doi/10.1128/AEM.71.11.6489-6500.2005
  45. https://www.frontiersin.org/journals/sustainable-food-systems/articles/10.3389/fsufs.2021.603892/full
  46. https://pubmed.ncbi.nlm.nih.gov/32325316/
  47. https://patents.google.com/patent/US20020147123A1/en
  48. https://www.researchgate.net/publication/265416330_Bacterial_constituents_of_indoor_air_in_a_high_throughput_building_in_the_tropics
  49. https://www.sciencedirect.com/topics/immunology-and-microbiology/micrococcus-luteus
  50. https://www.mdpi.com/2079-9284/11/4/122
  51. https://www.mdpi.com/2079-9284/12/3/105
  52. https://www.mdpi.com/2674-1334/4/4/51
Add your contribution
Related Hubs
Contribute something
User Avatar
No comments yet.